<DOC>
	<DOCNO>NCT01987843</DOCNO>
	<brief_summary>The primary objective study : - To evaluate safety tolerability three dose level MT-1303 subject moderate severe chronic plaque psoriasis . - To evaluate efficacy three dos level MT-1303 subject moderate severe chronic plaque psoriasis compare placebo 16 week treatment Psoriasis Area Severity Index ( PASI ) .</brief_summary>
	<brief_title>Dose-finding Study MT-1303 Subjects With Moderate Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Have diagnose plaque psoriasis least 6 month prior screen Have moderate severe chronic plaque psoriasis define PASI score ≥ 12 BSA ≥ 10 % baseline In investigator 's opinion candidate systemic therapy Nonplaque form psoriasis ( e.g. , guttate , erythrodermic pustular ) Current druginduced aggravated psoriasis ( e.g. , new onset psoriasis exacerbation psoriasis betablockers , calciumchannel blocker , lithium carbonate ) History list predefined cardiovascular disease History know presence significant infectious , metabolic , oncological , ophthalmological respiratory system disease illness likely render subject unsuitable study . Previous exposure S1P receptor modulator Receipt live vaccine within 28 day prior randomisation Need , likely need , treatment Class I III antiarrhythmic drug heartratelowering betablockers calciumchannel blocker , drug reduce heart rate Clinically significant finding electrocardiogram ( ECG ) finding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Plaque Psoriasis</keyword>
</DOC>